{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:50:53Z","timestamp":1790985053449,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.urolonc.2026.05.003","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T09:01:49Z","timestamp":1779872509000},"page":"51-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Serum levels of microRNA-371a-3p (M371) for prediction of histology in chemotherapy-na\u00efve patients with testicular germ cell tumours undergoing lymph node dissection\u2014a retrospective analysis of 57 cases"],"prefix":"10.1016","volume":"44","author":[{"given":"Klaus-Peter","family":"Dieckmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Angerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cansu","family":"Dumlupinar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilli","family":"Fiedeldey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Harms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"W\u00fclfing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8613-3450","authenticated-orcid":false,"given":"Gazanfer","family":"Belge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2026.05.003_bib0001","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.eururo.2021.06.006","article-title":"Circulating MicroRNAs, the next-generation serum biomarkers in testicular germ cell tumours: a systematic review","volume":"80","author":"Le\u00e3o","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0002","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15153944","article-title":"MicroRNA-371a-3p\u2014The novel serum biomarker in testicular germ cell tumors","volume":"15","author":"Nestler","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0003","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.18.01480","article-title":"Serum levels of microRNA-371a-3p (M371 Test) as a new biomarker of testicular germ cell-tumors: results of a prospective multicentric study","volume":"37","author":"Dieckmann","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0004","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.euf.2022.04.008","article-title":"Circulating MicroRNAs for detection of germ cell tumours: a narrative review","volume":"8","author":"Fankhauser","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0005","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16071379","article-title":"Advancing GCT management: a review of miR-371a-3p and other miRNAs in comparison to traditional serum tumor markers","volume":"16","author":"Seales","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0006","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1097\/JU.0000000000004164","article-title":"miR-371a-3p predicting viable tumor in patients undergoing retroperitoneal lymph node dissection for metastatic testicular cancer: the SWENOTECA-MIR study","volume":"212","author":"Thor","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0007","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.euf.2024.05.002","article-title":"Serum levels of MicroRNA-371a-3p for predicting the histology of postchemotherapy residual masses of germ cell tumours","volume":"10","author":"Dieckmann","year":"2024","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0008","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1200\/JCO.22.02002","article-title":"Plasma micro-RNA 371 expression in early-stage germ cell tumors: are we ready to move toward biology-based decision making?","volume":"41","author":"Alsyouf","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0009","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/JU.0000000000003694","article-title":"Diagnosis and treatment of early-stage testicular cancer: AUA Guideline Amendment 2023","volume":"211","author":"Stephenson","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0010","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000510407","article-title":"Management of germ cell tumours of the testis in adult patients. German clinical practice guideline part I: epidemiology, classification, diagnosis, prognosis, fertility preservation, and treatment recommendations for localized stages","volume":"105","author":"Kliesch","year":"2021","journal-title":"Urol Int"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0011","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.eururo.2023.04.010","article-title":"European Association of Urology Guidelines on testicular cancer: 2023 update","volume":"84","author":"Patrikidou","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0012","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.annonc.2022.01.002","article-title":"Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Oldenburg","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0013","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.urolonc.2024.01.014","article-title":"Primary retroperitoneal lymph node dissection for clinical stage II seminoma: a systematic review and meta-analysis of safety and oncological effectivenes","volume":"42","author":"Kardoust Parizi","year":"2024","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0014","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.euros.2024.05.006","article-title":"Primary retroperitoneal lymph node dissection as treatment for low-volume metastatic seminoma in a population-based cohort: the Swedish Norwegian Testicular Cancer Group experience","volume":"65","author":"Thor","year":"2024","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0015","article-title":"Feasibility and oncological safety of robotic retroperitoneal lymph node dissection in patients with testicular cancer-single-center experience","volume":"17","author":"Angerer","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0016","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1093\/jnci\/djaf014","article-title":"Factors associated with longitudinal progression of the cumulative burden of morbidity and overall mortality after cisplatin-based chemotherapy for testicular cancer","volume":"117","author":"Kerns","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0017","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkaa017","article-title":"Solid and hematologic neoplasms after testicular cancer: a US population-based study of 24 900 survivors","volume":"4","author":"Milano","year":"2020","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0018","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.eururo.2020.10.024","article-title":"Integrated expression of circulating miR375 and miR371 to identify teratoma and active germ cell malignancy components in malignant germ cell tumors","volume":"79","author":"Nappi","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0019","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.euo.2023.10.021","article-title":"Evaluation of a miRNA-371a-3p assay for predicting final histopathology in patients undergoing primary nerve-sparing retroperitoneal lymphadenectomy for stage IIA\/B seminoma or nonseminoma","volume":"7","author":"Seelemeyer","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0020","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.eururo.2019.10.005","article-title":"Serum MicroRNA-371a-3p levels predict viable germ cell tumor in chemotherapy-na\u00efve patients undergoing retroperitoneal lymph node dissection","volume":"77","author":"John","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0021","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/andr.13317","article-title":"Evaluation of miR-371a-3p to predict viable gwerm cell tumor in patients with pure seminoma receiving retroperitoneal lymph node dissection","volume":"11","author":"Konneh","year":"2022","journal-title":"Andrology"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0022","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s00345-025-05571-y","article-title":"Diagnostic efficacy of serum microRNAs in predicting pathology of retroperitoneal lymph node dissection in patients with testicular germ cell tumors: a systematic review and meta-analysis","volume":"43","author":"Kardoust Parizi","year":"2025","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0023","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0022-5347(17)42997-1","article-title":"Localization of solitary and multiple metastases in stage II nonseminomatous testis tumor as basis for a modified staging lymph node dissection in stage I","volume":"138","author":"Weissbach","year":"1987","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0024","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12894-018-0412-x","article-title":"Is there still a place for retroperitoneal lymph node dissection in clinical stage 1 nonseminomatous testicular germ-cell tumours? A retrospective clinical study","volume":"18","author":"Dieckmann","year":"2018","journal-title":"BMC Urol"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0025","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1158\/1078-0432.CCR-23-0730","article-title":"Detection of recurrence through microRNA-371a-3p serum levels in a follow-up of stage I testicular germ cell tumors in the DRKS-00019223 study","volume":"30","author":"Belge","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0026","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0027","doi-asserted-by":"crossref","first-page":"58037","DOI":"10.18632\/oncotarget.10867","article-title":"Accurate primary germ cell cancer diagnosis using serum based microRNA detection (ampTSmiR test)","volume":"8","author":"van Agthoven","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0028","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nrurol.2016.170","article-title":"The present and future of serum diagnostic tests for testicular germ cell tumours","volume":"3","author":"Murray","year":"2016","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0029","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/5030349","article-title":"Serum tumour markers in testicular germ cell tumours: frequencies of elevated levels and extents of marker elevation are significantly associated with clinical parameters and with response to treatment","volume":"2019","author":"Dieckmann","year":"2019","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0030","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ucl.2022.09.002","article-title":"Biomarkers in testicular cancer: classic tumor markers and beyond","volume":"50","author":"Egan","year":"2023","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0031","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2174\/1573405612666160606104815","article-title":"Role of imaging in testicular cancer","volume":"13","author":"Dulal","year":"2017","journal-title":"Curr Med Imaging Rev"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0032","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1097\/JU.0000000000000594","article-title":"Performance characteristics of clinical staging modalities in early-stage testicular germ cell tumors: a systematic review","volume":"203","author":"Pierorazio","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0033","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22052654","article-title":"Liquid biopsies in the clinical management of germ cell tumor patients: state-of-the-art and future directions","volume":"22","author":"Lobo","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0034","doi-asserted-by":"crossref","first-page":"163","DOI":"10.21873\/invivo.11757","article-title":"Serum level of microRNA-375-3p is not a reliable biomarker of teratoma","volume":"34","author":"Belge","year":"2020","journal-title":"In Vivo"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0035","doi-asserted-by":"crossref","DOI":"10.3390\/cells8121637","article-title":"Identification and validation model for informative liquid biopsy-based microRNA biomarkers: insights from germ cell tumor In vitro, In vivo and patient-derived data","volume":"8","author":"Lobo","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0036","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ucl.2024.03.007","article-title":"MicroRNA for prediction of teratoma and viable germ cell tumor after chemotherapy","volume":"51","author":"Baky","year":"2024","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0037","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.euros.2021.02.003","article-title":"Serum small RNA sequencing and miR-375 assay do not identify the presence of pure teratoma at postchemotherapy retroperitoneal lymph node dissection","volume":"26","author":"Lafin","year":"2021","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0038","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.juro.2018.02.068","article-title":"Serum miRNA predicts viable disease post-chemotherapy in testicular non-seminoma germ cell tumor patients","volume":"200","author":"Le\u00e3o","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0039","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14215447","article-title":"Testicular neoplasms: primary tumour size is closely interrelated with histology, clinical staging, and tumour marker expression rates - a comprehensive statistical analysis","volume":"14","author":"Dieckmann","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0040","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-94812-2","article-title":"Serum miR371 in testicular germ cell cancer before and after orchiectomy, assessed by digital-droplet PCR in a prospective study","volume":"11","author":"Myklebust","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115494","article-title":"Clinical evaluation of the role of miRNA 371 in small testicular masses. Results of the \"S1STeM 371\" trial","volume":"223","author":"Nazzani","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0042","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12030759","article-title":"Evaluation of circulating miRNA biomarkers of testicular germ cell tumors during therapy and follow-up-A Copenhagen experience","volume":"12","author":"M\u00f8rup","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0043","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.juro.2014.07.010","article-title":"Circulating serum microRNA (miR-367-3p, miR-371a-3p, miR-372-3p, miR-373-3p) as biomarkers for patients with testicular germ cell cancers","volume":"193","author":"Syring","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0044","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.3390\/cells8101221","article-title":"miR-371a-3p, miR-373-3p and miR-367-3p as serum biomarkers in metastatic testicular germ cell cancers before, during and after chemotherapy","volume":"8","author":"Rosas Plaza","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0045","first-page":"242","article-title":"Micro-RNA-371a-3p in germ cell testicular tumors on diagnosis: a prospective case-control study in Turkish population","volume":"21","author":"K\u0131l\u0131n\u00e7","year":"2024","journal-title":"Urol J"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0046","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1200\/JCO.18.02057","article-title":"Developing a highly specific biomarker for germ cell malignancies: plasma miR371 expression across the germ cell malignancy spectrum","volume":"37","author":"Nappi","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0047","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/JU.0000000000001337","article-title":"Real-world application of pre-orchiectomy miR-371a-3p test in testicular germ cell tumor management","volume":"205","author":"Badia","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0048","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.21873\/anticanres.16316","article-title":"Evaluation of the M371-test under real-life conditions for diagnosis and follow up of testicular germ cell tumors","volume":"43","author":"Pycha","year":"2023","journal-title":"Anticancer Res"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0049","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2017.0338","article-title":"Germ cell tumour subtypes display differential expression of microRNA371a-3p","volume":"373","author":"Vilela-Salgueiro","year":"2018","journal-title":"Philos Trans R Soc B"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0050","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1159\/000488284","article-title":"Testicular germ-cell tumours: a descriptive analysis of clinical characteristics at first presentation","volume":"100","author":"Dieckmann","year":"2018","journal-title":"Urol Int"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0051","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/1097-0142(19870801)60:3+<464::AID-CNCR2820601506>3.0.CO;2-C","article-title":"Biological markers in urologic cancer","volume":"60","author":"Lange","year":"1987","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2026.05.003_bib0052","doi-asserted-by":"crossref","DOI":"10.4414\/smw.2018.14640","article-title":"Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian german Testicular Cancer Cohort Study (SAG TCCS)","volume":"148","author":"Rothermundt","year":"2018","journal-title":"Swiss Med Wkly"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005223?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005223?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T22:29:35Z","timestamp":1783376975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926005223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":52,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1078143926005223"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.05.003","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum levels of microRNA-371a-3p (M371) for prediction of histology in chemotherapy-na\u00efve patients with testicular germ cell tumours undergoing lymph node dissection\u2014a retrospective analysis of 57 cases","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}